{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:39:05Z","timestamp":1790476745850,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000867","name":"Commonwealth Scholarship Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.drudis.2021.09.015","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T14:02:27Z","timestamp":1632837747000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Factors influencing the choice of monoclonal antibodies for antibody\u2013drug conjugates"],"prefix":"10.1016","volume":"27","author":[{"given":"Md. Mahbub","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5201-3768","authenticated-orcid":false,"given":"Mark","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-853X","authenticated-orcid":false,"given":"Peiqin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khondaker Miraz","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.09.015_b0005","first-page":"3","article-title":"Antibody-drug conjugates: possibilities and challenges","volume":"11","author":"Nejadmoghaddam","year":"2019","journal-title":"Avicenna J Med Biotechnol"},{"key":"10.1016\/j.drudis.2021.09.015_b0010","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2021.09.015_b0015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s magic bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2021.09.015_b0020","first-page":"1626","article-title":"Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts","volume":"246","author":"Mathe","year":"1958","journal-title":"C R Hebd Seances Acad Sci"},{"key":"10.1016\/j.drudis.2021.09.015_b0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/HAB-180348","article-title":"Antibody drug conjugates: progress, pitfalls, and promises","volume":"27","author":"Mukherjee","year":"2018","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.drudis.2021.09.015_b0030","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody\u2013drug conjugates: the new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2021.09.015_b0035","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2021.09.015_b0040","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved tumor penetration and single-cell targeting of antibody\u2013drug conjugates increases anticancer efficacy and host survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2021.09.015_b0045","unstructured":"Panitumumab IRDye800 Optical Imaging Study. In: https:\/\/ClinicalTrials.gov\/show\/NCT02415881 [accessed September 22, 2021]."},{"key":"10.1016\/j.drudis.2021.09.015_b0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19498-y","article-title":"Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates","volume":"11","author":"Lu","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2021.09.015_b0055","unstructured":"Non-internalizing ADC. Creative-Biolabs 2021. www.creative-biolabs.com\/adc\/non-internalizing-adc.htm [accessed September 22, 2021]."},{"key":"10.1016\/j.drudis.2021.09.015_b0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jconrel.2017.08.040","article-title":"A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo","volume":"264","author":"Dal Corso","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2021.09.015_b0065","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2018.12.018","article-title":"Secreted Gal-3BP is a novel promising target for non-internalizing antibody\u2013drug conjugates","volume":"294","author":"Giansanti","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2021.09.015_b0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/abt\/tbaa024","article-title":"Tackling solid tumour therapy with small-format drug conjugates","volume":"3","author":"Deonarain","year":"2020","journal-title":"Antibody Therap"},{"key":"10.1016\/j.drudis.2021.09.015_b0075","doi-asserted-by":"crossref","first-page":"e0192194","DOI":"10.1371\/journal.pone.0192194","article-title":"Generation of high-affinity, internalizing anti-FGFR2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers","volume":"13","author":"Borek","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2021.09.015_b0080","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/bs.mie.2020.02.021","article-title":"Expanding the substrate selectivity of SNAP\/CLIP-tagging of intracellular targets","volume":"638","author":"Macias-Contreras","year":"2020","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.drudis.2021.09.015_b0085","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.2147\/OTT.S140492","article-title":"Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells","volume":"10","author":"Woitok","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2021.09.015_b0090","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cmdc.201900077","article-title":"Characterization of disulfide bond rebridged Fab\u2013drug conjugates prepared using a dual maleimide pyrrolobenzodiazepine cytotoxic payload","volume":"14","author":"Ruddle","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2021.09.015_b0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/19420862.2019.1578611","article-title":"Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer","volume":"11","author":"White","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2021.09.015_b0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2018.06.016","article-title":"Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor","volume":"284","author":"Tsumura","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2021.09.015_b0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4155\/bio-2017-0186","article-title":"Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan","volume":"10","author":"Ishii-Watabe","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.drudis.2021.09.015_b0110","unstructured":"Immunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti\u2013Drug Antibody Detection. FDA. www.fda.gov\/media\/119788\/download [accessed September 22, 2021]."},{"key":"10.1016\/j.drudis.2021.09.015_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8958-4_1","article-title":"Human monoclonal antibodies: the benefits of humanization","volume":"1904","author":"Waldmann","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2021.09.015_b0120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/312548a0","article-title":"Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo","volume":"312","author":"Cobbold","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.09.015_b0125","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","article-title":"Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains","volume":"81","author":"Morrison","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2021.09.015_b0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.drudis.2021.09.015_b0135","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1126\/science.3285470","article-title":"Assembly of a functional immunoglobulin Fv fragment in Escherichia coli","volume":"240","author":"Skerra","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.drudis.2021.09.015_b0140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2021.09.015_b0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.drudis.2021.09.015_b0150","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.drudis.2021.09.015_b0155","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.4155\/bio-2018-0259","article-title":"Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials","volume":"11","author":"Carrasco-Triguero","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.drudis.2021.09.015_b0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2021.09.015_b0165","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jps.24338","article-title":"Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates","volume":"104","author":"Wiggins","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2021.09.015_b0170","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/9783527814695.ch3","article-title":"Antibody\u2013drug conjugates: empowering antibodies for the fight against cancer","volume":"4","author":"Denevault-Sabourin","year":"2019","journal-title":"Successful Drug Discovery"},{"key":"10.1016\/j.drudis.2021.09.015_b0175","doi-asserted-by":"crossref","first-page":"9785","DOI":"10.1021\/ac402237v","article-title":"Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and \u2018bispecific\u2019 monoclonal antibody formation","volume":"85","author":"Debaene","year":"2013","journal-title":"Anal Chem"},{"key":"10.1016\/j.drudis.2021.09.015_b0180","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1535-7163.MCT-08-0295","article-title":"Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index","volume":"7","author":"McDonagh","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2021.09.015_b0185","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"Vafa","year":"2014","journal-title":"Methods"},{"key":"10.1016\/j.drudis.2021.09.015_b0190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.drudis.2021.09.015_b0195","series-title":"Antibody-Drug Conjugates: Methods and Protocols","first-page":"83","article-title":"Click chemistry conjugations","author":"Chio","year":"2020"},{"key":"10.1016\/j.drudis.2021.09.015_b0200","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody-drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2021.09.015_b0205","series-title":"Antibody-Drug Conjugates: Methods and Protocols","first-page":"37","article-title":"Conjugations to endogenous cysteine residues","author":"Nadkarni","year":"2020"},{"key":"10.1016\/j.drudis.2021.09.015_b0210","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2021.09.015_b0215","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2021.09.015_b0220","series-title":"Antibody-Drug Conjugates: Methods and Protocols","first-page":"51","article-title":"Site-specific conjugation to cys-engineered THIOMAB\u2122 antibodies","author":"Adhikari","year":"2020"},{"key":"10.1016\/j.drudis.2021.09.015_b0225","series-title":"Antibody-Drug Conjugates","first-page":"189","article-title":"Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers","author":"Bhakta","year":"2013"},{"key":"10.1016\/j.drudis.2021.09.015_b0230","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/nar\/gku1362","article-title":"Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates","volume":"43","author":"Cuellar","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2021.09.015_b0235","doi-asserted-by":"crossref","first-page":"16101","DOI":"10.1073\/pnas.1211023109","article-title":"Synthesis of site-specific antibody\u2013drug conjugates using unnatural amino acids","volume":"109","author":"Axup","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2021.09.015_b0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ddtec.2018.09.004","article-title":"Homogeneous antibody-drug conjugates via site-selective disulfide bridging","volume":"30","author":"Forte","year":"2018","journal-title":"Drug Discovery Today: Technol"},{"key":"10.1016\/j.drudis.2021.09.015_b0245","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-4939-9546-2_13","article-title":"Site-specific antibody labeling using phosphopantetheinyl transferase-catalysed ligation","volume":"2012","author":"Gr\u00fcnewald","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2021.09.015_b0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-4939-9929-3_5","article-title":"Transglutaminase-mediated conjugations","volume":"2078","author":"Anami","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2021.09.015_b0255","doi-asserted-by":"crossref","first-page":"113615","DOI":"10.1016\/j.ab.2020.113615","article-title":"Recent progress in transglutaminase-mediated assembly of antibody\u2013drug conjugates","volume":"595","author":"Schneider","year":"2020","journal-title":"Anal Biochem"},{"key":"10.1016\/j.drudis.2021.09.015_b0260","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2021.09.015_b0265","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4939-9929-3_9","article-title":"Antibody conjugations via glycosyl remodeling","volume":"2078","author":"Toftevall","year":"2020","journal-title":"Methods Mol Biol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621004098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644621004098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:52:22Z","timestamp":1761223942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644621004098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1359644621004098"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.09.015","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing the choice of monoclonal antibodies for antibody\u2013drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}